Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL7845636 | 0.82 | TSHR (0.37) | TSHRCA5ACA5BALDH1A1 | |
| SCHEMBL17072311 | 0.82 | — | — | |
| SCHEMBL760206 | 0.82 | — | — | |
| SCHEMBL15349735 | 0.82 | — | — | |
| Nitric Acid SCHEMBL27927590 | 0.76 | — | — | |
| Nitric Acid SCHEMBL1840454 | 0.76 | CA5A (0.50) | TSHRCA5ACA5BALDH1A1 | |
| Nitric Acid SCHEMBL8379441 | 0.76 | CA5A (0.50) | TSHRCA5ACA5BALDH1A1 | |
| Formic Acid SCHEMBL3387310 | 0.75 | TSHR (0.43) | TSHR | |
| Butanol SCHEMBL8105837 | 0.74 | TSHR (0.59) | TSHRCA5ACA5BALDH1A1 | |
| SCHEMBL2637044 | 0.73 | TSHR (0.42) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2115106-A2 | NEUROPROTECTION BY BLOOD FLOW STABILIZATION | Catholic Healthcare West (D/B/A St. Joseph's Hospital Medical Center) (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008080009-A2 | NEUROPROTECTION BY BLOOD FLOW STABILIZATION | CATHOLIC HEALTHCARE WEST (D/B/A ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER) (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1083887-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ULCERS | NICOX SA (FR) | 2005-10-05 | — | — | EP | disclosed |
| US-20030027844-A1 | Pharmaceutical compositions for ulcer | NICOX S.A. | 2003-02-06 | — | — | US | disclosed |
| US-6436975-B1 | ANTIULCER AND ANTISECRETORY AGENTS, COMPRISING MIXTURES OF MERCAPTANS AND NITRO COMPOUNDS; PROPHYLAXIS OF IRRITABLE BOWEL SYNDROME | NICOX S.A. (FR) | 2002-08-20 | — | — | US | disclosed |
| EP-1083887-A2 | PHARMACEUTICAL COMPOSITIONS FOR ULCER | NICOX S.A. (FR) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999044595-A2 | PHARMACEUTICAL COMPOSITIONS FOR ULCER | NICOX S.A. (FR) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027844-A1 | Pharmaceutical compositions for ulcer | NOS2, NOS1, NOS3 | TSHR 4446/4885CA5A 1949/4885CA5B 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.